Goldman Sachs initiates Oklo stock with Neutral rating, $117 price target

Goldman Sachs initiated coverage on nuclear energy firm Oklo (OKLO) with a Neutral rating and a $117 price target, implying 11% downside from current levels, despite the stock's 1,490% surge and current trading above fair value. Oklo is developing advanced reactors and investing in HALEU fuel production, capitalizing on a resurgent nuclear market, though its capital-intensive own-and-operate model presents financial risks. Analyst sentiment is notably mixed, with some firms downgrading on valuation while others raise price targets, highlighting divergent views on the company's high-growth strategy and future catalysts.

Analysis

Goldman Sachs has initiated coverage on Oklo (OKLO) with a Neutral rating and a $117 price target, implying an 11% downside following the stock's 1,490% surge over the past year. This cautious stance aligns with data indicating the stock is trading above its fair value and a recent downgrade to Neutral by Seaport Global Securities, both citing valuation concerns. Oklo is developing its Aurora Powerhouse reactor with a commercialization target of late 2027 or early 2028, but its capital-intensive own-and-operate model and reliance on High-Assay Low Enriched Uranium (HALEU) present significant financial and supply chain risks. Despite these risks, Oklo is capitalizing on positive policy momentum for nuclear energy, has broken ground at the Idaho National Laboratory, and plans a $1.68 billion investment in a HALEU fuel facility to address supply bottlenecks. The analyst community remains sharply divided, with Wedbush raising its price target to $150 while UBS maintains a Neutral rating with a $65 target, underscoring a conflict between the company's long-term strategic potential and its current, elevated valuation.

Key Decisions for Investors

• Given the stock's 1,490% run-up and multiple neutral ratings citing valuation, investors should be cautious of the potential for a downside correction from current levels.
• Closely monitor near-term catalysts, including Nuclear Regulatory Commission licensing progress and announcements of power purchase agreements, which are critical for justifying the stock's elevated valuation.
• Evaluate the significant execution risks associated with the capital-intensive business model and the HALEU fuel bottleneck, making progress on the planned fuel facility a key de-risking milestone to watch.
• The wide dispersion in analyst price targets, from $65 to $150, signals significant uncertainty, positioning the stock as a high-risk, catalyst-driven investment rather than one based on current fundamentals.